Management

Patients with a longer duration of untreated psychosis (DUP) have a better long-term prognosis.

Physical examination for metabolic syndrome is a part of the assessment of treatment-resistant schizophrenia.

Early Intervention in Psychosis Service (EIS) teams were mandated in the UK in the 2010 NHS Plan.

There is convincing evidence that early intervention reduces the duration of untreated psychosis.

Low-dose medication and cognitive behavioural approaches may decrease the conversion to psychosis.

Omega-3 polyunsaturated fatty acids have shown no effect on reducing the risk of onset of psychosis.

The treatment response becomes quicker and more frequent during subsequent psychotic episodes.

Patients' views regarding treatment should be discussed during the assessment of treatment-resistant schizophrenia.

Substance misuse among schizophrenia patients is associated with decreased risks of homelessness.

Clozapine has shown some efficacy in reducing cannabis use among schizophrenia patients.

Fazel et al. (2014a) found that 2.7% of male schizophrenia patients were convicted of a violent offence within 5 years of diagnosis.

Patients with schizophrenia are more likely to be perpetrators of violence than victims.

Clozapine and paliperidone extended release are beneficial for patients with persistent hostility and violence.

Both male and female schizophrenia patients are less likely to be convicted of violent offenses within 5 years of diagnosis.

There is comprehensive evidence supporting the efficacy of integrated outpatient programs for managing substance misuse and psychotic illness in schizophrenia patients.

Comorbid depression and hopelessness are risk factors for suicide in schizophrenic patients.

Patients with pronounced negative symptoms are more likely to make suicide attempts.

Clozapine and antidepressants have been associated with reduced suicide rates in schizophrenia.

Care Programme Approach (CPA) is only implemented in the UK for patients with schizophrenia.

A key worker is assigned to maintain contact with patients and ensure the delivery of the treatment programme.

Schizophrenia treatment does not require regular reviews.

Depot injections are often used to help with medication adherence in schizophrenia patients.

Patients with schizophrenia usually return to their premorbid level of functioning.

CBT and other psychological interventions can be part of the integrated care package for schizophrenia management.

Once stabilized after an acute episode, medication for schizophrenia should typically continue for at least 1-2 years.

The severity and nature of residual symptoms of schizophrenia determine the extent and duration of ongoing care.

The term schizophrenia should always be used carefully and sensitively due to its association with considerable stigma and misunderstanding.

Discussion about schizophrenia should avoid any mention of its heritability to prevent unnecessary concern among patients and carers.

The 'Recovery Approach' emphasizes the goal of eliminating the illness entirely.

Psychiatrists should concern themselves more with whether a patient's thought is delusional than with its content and meaning for the patient.

The family environment and substance misuse are psychosocial factors that can influence the outcome of schizophrenia treatment.

After establishing heritability, it is not necessary to address increased risk concerns regarding schizophrenia in future generations.

Parents should be reassured that their behavior is not a cause of schizophrenia in their children.

The 'Recovery Movement' criticizes psychiatrists for being too optimistic about the prognosis in schizophrenia.

Psychiatrists should adapt their approach to discussing schizophrenia according to the circumstances of each case.

The involvement of the family in schizophrenia treatment decisions can be disregarded if it differs significantly from the clinical team's views.

A test dose is necessary for both typical and atypical antipsychotic depot preparations.

Olanzapine pamoate must be monitored for at least 3 hours post injection due to potential serious side effects.

Maximum plasma concentrations of depot preparations are reached within a few days.

About 2% of patients experience excessive sedation, confusion, or coma from olanzapine pamoate.

Clozapine is rarely used for treatment-resistant schizophrenia due to its lack of effectiveness.

Patients with chronic schizophrenia may require interventions for cognitive and social functioning.

Support for family and carers has not been proven to be valuable in the management of treatment-resistant schizophrenia.

One in three patients with schizophrenia is considered to have treatment-resistant schizophrenia.

Patients with chronic schizophrenia do not need monitoring for comorbid conditions or substance misuse.

Patients receiving depot antipsychotic treatment should continue to take oral antipsychotic medication without tapering the doses.

Early intervention is important only for the first episode of schizophrenia.

Cognitive behavioural therapy is one component of treatment for schizophrenia.

Olanzapine is recommended as a first-line treatment for first episode psychosis due to its lower risk of metabolic syndrome.

Antipsychotic medication is the mainstay of the treatment of schizophrenia.

It is common for patients to be able to engage fruitfully in specific psychological therapies during the early stages of treatment.

Metabolic syndrome in first-episode psychosis is present in about 50% of patients.

Assertive outreach is a treatment component for vulnerable patients with schizophrenia.

Integrated, multidisciplinary working involves solely primary care.

Risperidone, amisulpride, and aripiprazole are suggested antipsychotic drugs for first episode psychosis.

Physical examinations and routine investigations should be carried out to provide baseline data for metabolic syndrome monitoring.

Successful management of schizophrenia always requires strict hospitalization for the first episode.

A thorough assessment often requires multiple interviews due to the patient's withdrawn or suspicious nature.

The development of crisis teams has conclusively proven to reduce hospital admissions.

The importance of medication, including its limitations and side effects, should always be clearly communicated to the patient and their carers.

An updated knowledge of novel service delivery methods is considered irrelevant to the management of schizophrenia.

Clinical guidelines for the management of schizophrenia are optional and not critical for making management decisions.

The first step in managing schizophrenia is forming a good relationship with the patient.

Hospital admission for the first episode of schizophrenia never involves the use of the Mental Health Act.

Antipsychotic Depot Prep

Test Dose

Treatment-Resistant Schizophrenia

Clozapine

Agranulocytosis

Comorbid Conditions

Substance Misuse

Recovery Approach

Early Intervention

Treatment Adherence

Hospital Admission

Crisis Teams

Violence in Schizophrenia

Suicide Risk

Cognitive Remediation

Social Skills Training

Patient Assessment

Monitoring of Comorbidities

Realistic Plans

Medication Explanation

Patient Relationship

Schizophrenia in children/adolescents